Rare genetic diseases collectively affect hundreds of millions of people worldwide

Neurological Disorders
Muscular Dystrophies
Ocular Diseases
Oncology

The next generation of gene silencing technology

NeuBase has developed a modular antisense peptide nucleic acid (PNA) platform with the capability to address rare genetic disease caused by mutant proteins with a single, cohesive approach. NeuBase has improved gene silencing therapies to include the advantages of synthetic approaches with the precision of antisense technologies.

Technology

The advantages of the NeuBase PATrOL™ platform enable the company to cohesively develop therapies for a wide range of rare genetic diseases, including repeat expansion disorders, dominant and recessive genetic disorders and cancers driven by specific oncogenic mutations.

NeuBase is first addressing Huntington’s disease and myotonic dystrophy.

Read More

The NeuBase technology has several advantages over traditional ASOs

Sd

Scalable & Modular Development

Pre-organized peptide backbone and toolkit of engineered nuclear bases allow drugs to be quickly snapped together for many targets

Ts

Targeting Secondary RNA Structures

Higher specificity for mutant over wild type transcript, allowing for fewer off-target effects and more effective deactivation of disease-related mRNA

Sa

Systemic Administration

Ability to cross the blood brain barrier and disseminate broadly, allowing for systemic administration in neurological indications

Ni

No Immune Response

Do not cause an immune response when systemically administered, enabling us to develop solutions for pre-symptomatic individuals who are gene positive

NeuBase Therapeutics Initiates Trading on NASDAQ Under Ticker Symbol “NBSE”

PITTSBURGH, July 15, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today that its common stock began trading on The Nasdaq Capital Market under the ticker symbol “NBSE” at the open of market trading today, July 15, 2019, and will cease using the previous ticker symbol, “OHRP”.

Read More

NeuBase Therapeutics Closes Merger Transaction with Ohr Pharmaceutical

Company expects to initiate trading on NASDAQ Under Ticker Symbol “NBSE” effective July 15, 2019

Company completes previously announced financing of approximately $9 million immediately prior to closing of the merger

 Greenlight Capital agrees to purchase ~9% of NeuBase Therapeutics common stock in a private placement immediately following the merger closing

Read More

NeuBase Therapeutics to Participate in Roth RNA Revolution Conference

PITTSBURGH, July 11, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that Dietrich Stephan, Ph.D., NeuBase’s chief executive officer, will participate in two panel discussions as well as 1x1 meetings with investors at the Roth RNA Revolution Conference being held in New York City on July 17, 2019.

Read More

NeuBase Therapeutics to Present at the LD Micro Conference

PITTSBURGH, June 05, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer, will present a corporate overview and business update at the LD Micro 9th Annual Invitational, being held at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Read More